The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Acalabrutinib meets primary endpoint in ELEVATE-RR trial for patients with R/R CLL
On January 25, 2021, it was announced that acalabrutinib has met its primary endpoint of non-inferior progression-free survival compared with ibrutinib in the ELEVATE-RR trial of adults with relapsed/refractory, high-risk chronic lymphocytic leukemia (CLL).1
The phase III trial is the first to compare two Bruton’s tyrosine kinase inhibitors in CLL, and has also met a secondary endpoint for safety, showing a significantly lower incidence of atrial fibrillation compared with patients treated with ibrutinib.1
ELEVATE-RR (NCT02477696) is a multicenter, open label, phase III non-inferiority study of acalabrutinib vs ibrutinib in patients with previously treated high-risk CLL (presence of 17p and/or 11q deletion). The primary endpoint was progression-free survival. Secondary endpoints were incidence of treatment-emergent Grade ≥ 3 infections, incidence of Richter’s transformation, incidence of atrial fibrillation, and overall survival.
Acalabrutinib is approved in the U.S. and Europe for the treatment of adult patients with CLL. The ELEVATE-RR trial data is to be presented at an upcoming medical meeting and shared with health authorities.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content